Indie Asset Partners’s Royalty Pharma RPRX Stock Holding History

Indie Asset Partners’s Portfolio RPRX Stock Details RPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-433,000	Closed	-$12.2M	–	95
2023 Q4	$12.2M	Hold	433,000	–	–	10.97%	2
2023 Q3	$11.8M	Hold	433,000	–	–	11.85%	2
2023 Q2	$13.3M	Hold	433,000	–	–	14.48%	2
2023 Q1	$15.6M	Sell	433,000 -29,000	-6%	-$1.08M	18.22%	2
2022 Q4	$18.3M	Sell	462,000 -59,750	-11%	-$2.49M	20.01%	2
2022 Q3	$21M	Sell	521,750 -49,838	-9%	-$2.13M	21.48%	2
2022 Q2	$24M	Sell	571,588 -185,286	-24%	-$7.6M	21.21%	1
2022 Q1	$29.5M	Sell	756,874 -49,108	-6%	-$1.93M	22.15%	1
2021 Q4	$32.1M	Buy	805,982 +104,659	+15%	+$4.07M	23.31%	1
2021 Q3	$25.3M	Sell	701,323 -10,300	-1%	-$400K	20.53%	1
2021 Q2	$29.2M	Buy	711,623 +695,600	+4,341%	+$29.6M	23.64%	1
2021 Q1	$699K	Sell	16,023 -3,695	-19%	-$175K	0.8%	29
2020 Q4	$987K	Sell	19,718 -3,570	-15%	-$151K	1.15%	18
2020 Q3	$980K	Buy	23,288 +13,960	+150%	+$599K	1.23%	17
2020 Q2	$427K	Buy	+9,328	New	+$462K	0.54%	48

Other funds holding RPRX

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Indie Asset Partners's RPRX Position: Q1 2024 in Review

Indie Asset Partners sold out of Royalty Pharma (RPRX) in Q1 2024, closing a stake of 433,000 shares — an estimated $12.2M sold.

Indie Asset Partners first reported a position in RPRX in Q2 2020 and held it in 15 quarters. The position peaked at $32.1M in Q4 2021. 378 funds tracked by Wall St. Rank hold RPRX as of Q1 2024.

Indie Asset Partners reported no remaining Royalty Pharma position as of Q1 2024 after selling out during the quarter.
Indie Asset Partners sold 433,000 Royalty Pharma shares in Q1 2024, an estimated $12.2M.
Indie Asset Partners first reported a position in Royalty Pharma in Q2 2020 and held it in 15 quarters.
Indie Asset Partners's Royalty Pharma position peaked at $32.1M in Q4 2021.
378 funds tracked by Wall St. Rank held Royalty Pharma as of Q1 2024.

Based on Indie Asset Partners's 13F filing for Q1 2024, filed 10 May 2024.